Mumbai-based Lupin’s US subsidiary has acquired Symbiomix Therapeutics for $150m in an all-cash deal to expand its branded women’s health specialty business.
Founded in 2012, Symbiomix Therapeutics, which is based in Newark, New Jersey, is focused on developing therapies for gynecologic infections that can have serious health implications.
Through its acquisition, Lupin adds Symbiomix’ lead candidate Solosec (secnidazole) oral granules. Solosec, a 5-nitroimidazole antimicrobial agent, had secured the approval from the US Food and Drug Administration (FDA) for the treatment of bacterial vaginosis (BV) in adult women.
Solosec’s approval in the US was backed by various studies including two key trials in bacterial vaginosis along with an open label safety study which proved efficacy for single-dose of the drug in 2g strength.
According to Lupin, Solose is the first and only single dose oral treatment indicated for bacterial vaginosis, a very common gynecologic infection in the US, annually affecting 21 million women aged between 14 and 49.
Lupin CEO Vinita Gupta said: “We are delighted to complete the acquisition of Symbiomix and its Solosec brand, which immediately expands Lupin’s US women’s health specialty business into the highly-complementary gynecological infection sector.
“This transaction is an important milestone in the evolution of our Specialty business and gives Lupin a new therapeutic to bring to obstetricians and gynecologists to treat a serious health condition they see frequently in their practices.”
Lupin anticipates the commercial launch of Solosec in the US to be in mid-2018. The drug has been given a Qualified Infectious Disease Product (QIDP) designation by the FDA for bacterial vaginosis. With the QIDP, Solosec will be eligible for a minimum of 10 years of exclusivity in the US.
The bacterial vaginosis drug will join Methergine (methylergonovine) tablets, regarded as the anchor of Lupin’s branded women’s health specialty business.
Source: PBR
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.
